IL-17

      Xeligekimab in AS:
      -IL-17A blocker
      -Phase 3 study on Chinese pts showed sustained efficacy until week 48.
      -Significant i

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt
      📊 POS0574 @rheumnow #EULAR2025Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA

      Jiha Lee JihaRheum

      4 months 2 weeks ago

      📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3

      Early PsA? Treat fast, treat hard.

      The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 res

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR
      IL17i + JAKi 10.5 PY = 1 mild infectio

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ
      Can IL-17F signalling be modulated by treatment with TNFi?
      In PsA pts non responders to previous TNFi, there was increas

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz
      Early intensive therapy in PsA.
      STAMP RCT in early PsA:
      •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
      •MDA at

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX
      STAMP RCT early SEC vs. SoC 120pts
      Retention 58% vs 30%
      ACR 20, 50, 70 and MDA: better outcome at Month 3 but no differe

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      STAMP RCT early SEC vs. SoC 120pts Retention 58% vs 30% ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6 Dactylitis no difference Of note here SoC was a tight T2T strategy! @RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
      PMR,flag
      Secukinumab promise in PMR is real
      4 months 2 weeks ago
      Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

      Catch up on Conference Podcasts

      ×